Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Liquid Certolizumab Pegol in Rheumatoid Arthritis (Follow-up Study)
NCT00160641Phase 3Completed
- Sponsor
- UCB
- Start
- Nov 2005
- Primary completion
- Feb 2012
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 13
01
Overview
A Phase 3 trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by UCB. Started Nov 2005; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00160641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00160641.